Ashlins Pharmaceuticals and Lee's Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million

Source Summary

NEW YORK--(BUSINESS WIRE)--Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize certain drug products incorporating Lee’s Pharm’s interferon alp